Log in
Show password
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Seagen Inc.
  6. News
  7. Summary
    SGEN   US81181C1045


SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Seagen to Highlight New Data in Advanced Breast Cancer at 2021 San Antonio Breast Cancer Symposium

11/19/2021 | 09:33am EST

Seagen Inc. announced upcoming data presentations for TUKYSA? (tucatinib) at the San Antonio Breast Cancer Symposium (SABCS), taking place December 7-10, 2021. Seven abstracts including three spotlight posters - highlight the company?s commitment to addressing unmet needs in advanced breast cancer. Two abstracts featured in spotlight poster presentations show: Continued Clinical Benefit in HER2-Positive Metastatic Breast Cancer Patients (MBC) with Active and Stable Brain Metastases. Updated exploratory results from the pivotal HER2CLIMB trial showed that TUKYSA combined with trastuzumab and capecitabine resulted in a robust and durable prolongation of overall survival (OS) that was consistent with results from the primary analysis for HER2-positive metastatic breast cancer patients with brain metastases after an additional 15.6 months of follow-up. The benefit was maintained in patients with active and stable brain metastases. These results will be featured in a spotlight poster (Abstract #PD4-04) presented by Nancy U. Lin, M.D., Director of the Metastatic Breast Cancer Program in the Susan F. Smith Center for Women?s Cancers at Dana-Farber in Boston, MA. Promising Activity of TUKYSA Regimen in HER2-Positive MBC Patients with Leptomeningeal Metastases: A single-arm, investigator-sponsored phase 2 trial (n=17) of TUKYSA combined with trastuzumab and capecitabine represents the first prospective evidence of a systemic regimen demonstrating clinical benefit for HER2-positive breast cancer patients with leptomeningeal metastases, cancer that has spread to the membranes lining the brain and spinal cord. The findings showed a median OS of nearly one year (11.9 months [95% Confidence Interval: 4.1, NR]). Patients with leptomeningeal disease have a historically poor prognosis with median survival of four to five months. The most common treatment for leptomeningeal metastases is radiation therapy. These results will be featured in a spotlight poster (Abstract #PD4-02) presented by Rashmi Murthy, M.D., University of Texas MD Anderson Cancer Center. Patients with HER2-positive breast cancer have tumors with high levels of a protein called human epidermal growth factor receptor 2 (HER2), which promotes the growth of cancer cells. Up to 50% of metastatic HER2-positive breast cancer patients develop brain metastases over time. In 2020, more than two million new cases of breast cancer were diagnosed worldwide. Between 15% and 20% of breast cancer cases are HER2-positive.

ę S&P Capital IQ 2021
All news about SEAGEN INC.
01/25Seagen Canada Announces Availability of PADCEV« to Treat Advanced Bladder Cancer
01/18Seagen Reports Data From SEA-CD40 in Combination With Other Therapies in Metastatic Pan..
01/18Seagen Inc. Announces Data from Phase I Clinical Trial Combining SEA-CD40
01/18Morgan Stanley Adjusts Seagen Price Target to $178 From $181, Maintains Equalweight Rat..
01/18Seagen to Host Conference Call and Webcast Discussion of Fourth Quarter and Full Year 2..
01/14Pieris Doses First Patient in Phase 2 Gastric Cancer Trial of Cinrebafusp Alfa
01/06INSIDER SELL : Seagen
2021INSIDER SELL : Seagen
2021European Committee Recommends Astellas Pharma's Bladder Cancer Drug for Approval
2021Seagen to Present at the J.P. Morgan Healthcare Conference
More news
Analyst Recommendations on SEAGEN INC.
More recommendations
Financials (USD)
Sales 2021 1 549 M - -
Net income 2021 -647 M - -
Net cash 2021 2 348 M - -
P/E ratio 2021 -34,5x
Yield 2021 -
Capitalization 22 475 M 22 475 M -
EV / Sales 2021 13,0x
EV / Sales 2022 9,35x
Nbr of Employees 2 092
Free-Float 99,3%
Duration : Period :
Seagen Inc. Technical Analysis Chart | SGEN | US81181C1045 | MarketScreener
Technical analysis trends SEAGEN INC.
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 21
Last Close Price 122,91 $
Average target price 189,89 $
Spread / Average Target 54,5%
EPS Revisions
Managers and Directors
Clay B. Siegall Director & Chief Scientific Officer
Todd E. Simpson Chief Financial Officer
Vaughn B. Himes Chief Technical Officer
Roger D. Dansey Chief Medical Officer
Marc E. Lippman Independent Director
Sector and Competitors
1st jan.Capi. (M$)
SEAGEN INC.-20.08%22 592
MODERNA, INC.-38.99%62 828
LONZA GROUP AG-20.54%48 784
IQVIA HOLDINGS INC.-17.54%44 443
CELLTRION, INC.-25.51%18 165